How has Travere Therapeutics, Inc.'s other commercial liabilities changed year-over-year?

Travere Therapeutics, Inc.'s other commercial liabilities increased by 35.4% year-over-year, from $77.11M to $104.41M.

What is the long-term trend for Travere Therapeutics, Inc.'s other commercial liabilities?

Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s other commercial liabilities has grown at a 17.3% compound annual growth rate (CAGR), from $56.79M to $126.04M.

Travere Therapeutics, Inc. TVTX Other Commercial Liabilities

Other Commercial Liabilities at other companies

Vertex PharmaceuticalsVRTX

——

Vera TherapeuticsVERA

——

Ultragenyx PharmaceuticalRARE

——

Catalyst PharmaceuticalCPRX

——

Viridian Therapeutics, Inc.VRDN

——

ANI PharmaceuticalsANIP

——

Other financials

Income statement

See full

Revenue$127.2M+55.6%

Gross profit$125.2M+62.5%

Operating income-$36.9M+13.5%

Net income-$37.1M+10.0%

EPS (diluted)-$0.40+14.9%

Balance sheet

See full

Cash & equivalents$78.4M+26.6%

Total debt$15.6M-82.6%

Total equity$98.7M+201%

Total assets$555.2M+1.2%

Cash flow

See full

Operating cash flow-$40.4M+4.3%

CapEx$140.0K—

Free cash flow-$42.5M+28.1%

Valuation

See full

Market cap$5.2B+72.3%

Profitability

See full

Gross margin98.6%+2.6pp

Operating margin-10.6%-5.0pp

Net margin-20.3%-9.5pp

FCF margin-133.9%-34.4pp

Returns & leverage

See full

Return on equity-706%-1,302pp

Debt / equity0.2×-2.6×

Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s other commercial liabilities?: Travere Therapeutics, Inc. (TVTX) reported other commercial liabilities of $104.41M in Q1 2026.
How has Travere Therapeutics, Inc.'s other commercial liabilities changed year-over-year?: Travere Therapeutics, Inc.'s other commercial liabilities increased by 35.4% year-over-year, from $77.11M to $104.41M.
What is the long-term trend for Travere Therapeutics, Inc.'s other commercial liabilities?: Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s other commercial liabilities has grown at a 17.3% compound annual growth rate (CAGR), from $56.79M to $126.04M.